LONDON, February 16, 2013 /PRNewswire/ --
A new report by Visiongain predicts that the world antithrombotic drug market will reach revenue of $24.3 billion in 2015. That pharma market generated $22.7 billion in 2011, according to Antithrombotic Drugs: World Market 2013-2023, published in February 2013. Visiongain is a business information provider based in London, UK.
That study shows the overall market for antithrombotic drugs will expand steadily from 2013 to 2023. This expansion is due to rising disease prevalence and increases in healthcare spending in developing countries. The strength of the antithrombotic drug market stems from the high profile of the conditions associated with thrombotic disease, which require long term drug treatment, generating a high volume of long-term drug sales. That market holds great promise, for existing drugs and products under development.
Jennifer Taylor, a pharmaceutical industry analyst in visiongain, said: "The antithrombotic drug market is currently suffering from the loss of patent protection of the two leading drugs, Plavix and Lovenox. However, the market will soon recover with the establishment of novel oral anticoagulants on the market. Eliquis has recently received FDA approval and will soon capture a predominant share of the novel oral anticoagulant market. One major unmet need driving the antithrombotic drug market is that of an antidote for these novel oral anticoagulants. There are several antidotes in the R&D pipeline; when approved, those agents can look forward to a share of a $2 billion submarket.
"The establishment of those novel oral anticoagulants will change the face of the antithrombotic drug market. Currently, platelet aggregation inhibitors are the leading therapeutic class. However, the rapid growth in revenue of the direct thrombin inhibitor and direct factor Xa inhibitor therapeutic subclasses means anticoagulant drugs will become the leading group in that market within our forecast period."
Visiongain's report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. It forecasts the world-level submarkets of platelet aggregation inhibitors, anticoagulants and fibrinolytics.
The study also forecasts the main subclasses of anticoagulant drug:
- Heparins
- Vitamin K antagonists
- Direct thrombin inhibitors
- Direct factor Xa inhibitors.
To 2023, the report forecasts revenues of leading products, including Plavix, Lovenox, Pradaxa, Pletal and Aggrenox, as well as sales of newer drugs - Effient, Brilinta, Xarelto and Eliquis. The work also forecasts national markets to 2023: the US, Japan, Germany, France, Italy, the UK, Spain (EU5), Brazil, Russia, India and China (BRIC). Other analyses include a review of R&D and research interviews with authorities in academia, medicine and industry.
Antithrombotic Drugs: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning Visiongain report the Antithrombotic Drugs: World Market 2013-2023 please visit: http://www.visiongain.com/Report/982/Antithrombotic-Drugs-World-Market-2013-2023
For an executive summary please contact: Sara Peerun sara.peerun@visiongainglobal.com or Tel: +44 (0) 20 7336 6100
Companies Listed
Ablynx
Alchemia
Alchemix
American Heart Association (AHA)
Amphastar Pharmaceuticals
ARCA Biopharma
Armetheon Inc.
ARYx Therapeutics
Asahi Kasei Pharma America
AstraZeneca
Barr Pharmaceuticals
Bayer
Baylor College of Medicine
Bharat Biotech
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb
Canyon Pharmaceuticals
Centers for Disease Control and Prevention (CDC)
D. Western Therapeutics Institute
Daiichi Sankyo
Dr. Reddy's Laboratories
Eli Lilly
Endotis Pharma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Gate Pharmaceuticals
Genentech
GlaxoSmithKline
Grifols Therapeutics
ISIS Pharmaceuticals
Johnson & Johnson
Kowa
Kyowa Hakko
LG Life Sciences
LIMES Institute
Lundbeck
Merck & Co.
Mitsubishi Kasei
Momenta Pharmaceuticals
Mount Sinai School of Medicine
Mylan Pharmaceuticals
National Health Service (NHS)
National Institute for Clinical Excellence (NICE)
Novartis
Organon
Otsuka Pharmaceutical Company
Pfizer
Pharmacyclics
PLx Pharma
Polymedix
Portola Pharmaceuticals
Pozen
Regado Biosciences
Roche
Sandoz (part of Novartis)
Sanofi
Teva Pharmaceutical Industries
The Medicines Company
The Mount Sinai Medical Center
ThromboGenics
University of Insubria
Virginia Commonwealth University
Watson Pharmaceuticals
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100
